Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 15, 2019 (8 years ago)

Etomidate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Subpotent Drug.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Etomidate Injection, USP 20 mg/10mL (2mg/mL) 10 mL Single-Dose Vial, Rx only, Manufactured for: Heritage Pharmaceuticals Inc. Made in India, NDC 23155-160-31

Affected NDC 23155-0160-31

Compare with the code on your package — it is the most precise check available.

Drug: Etomidate

Recalling firm
Heritage Pharmaceuticals, Inc.
NDC code
23155-160-31
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1065-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Etomidate recalls

See all
Class III · Low risk

Amidate (Etomidate Injection, USP)

Failed Impurities/Degradation Specifications: Out of Specification(OOS) results for degradation product of etomidate was confirmed during stability testing.

Ongoing Impurity / degradation Hospira Inc. NDC 0409-8060-29 D-0054-2016
Class II · Moderate risk

Etomidate active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-665-2015
Class II · Moderate risk

etomidate injection

Presence of Particulate Matter: Potential for small black particles to be present in individual vials, the potential for missing lot number and/or expiry date on the outer carton and the potential for illegible/missing lot number and expiry on individual vials.

Terminated Particulate / foreign matter Agila Specialties Private Ltd. NDC 0069-0006-02 D-1225-2014
Class II · Moderate risk

Etomidate 0.2%

Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012 because FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.

Terminated Sterility / contamination Franck's Lab Inc., d.b.a. Franck's Compounding Lab D-1517-2012

Other recalls by Heritage Pharmaceuticals, Inc.

All 2019 recalls
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-583-25 D-0112-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-582-01 D-0111-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-581-01 D-0110-2026